Fatma Yurt | Nanomedicine | Best Researcher Award

Prof. Dr. Fatma Yurt | Nanomedicine | Best Researcher Award

Ege University | Turkey

Prof. Dr. Fatma Yurt is a Professor at the Institute of Nuclear Sciences, Ege University, İzmir, Türkiye, where she serves as Coordinator of the Nuclear Applications Program and has previously directed the Institute. She earned her B.Sc. in Chemistry and her Ph.D. in Nuclear Sciences, both from Ege University, and has become a leading academic and researcher in radiopharmacy, nuclear medicine, pharmaceutical technology, radiation shielding, photodynamic therapy, and imaging of infections and cancers. Her pioneering work bridges fundamental nuclear sciences with translational medical applications, with a particular focus on radiopharmaceuticals, radionuclide diagnostics, and innovative therapeutic strategies for cancer and other diseases. Prof. Yurt has published 133 documents, which have been cited 1,613 times across 1,208 documents, achieving an h-index of 22, reflecting her strong international research impact. Her recent research has explored multifunctional nanomaterials, targeted drug delivery systems, and hybrid therapeutic-imaging platforms that integrate photothermal, photodynamic, and chemotherapeutic effects, underscoring her interdisciplinary approach to advancing nuclear applications in medicine. She has also contributed significantly to the development of novel radiolabeling techniques, biosensing strategies, and in vitro and in vivo evaluation methods, demonstrating a commitment to both basic and applied science. In addition to her extensive research contributions, she is a dedicated educator and mentor, fostering the next generation of scientists while contributing to academic leadership, curriculum development, and international collaborations at Ege University, ensuring the growth and global recognition of nuclear sciences research in Türkiye.

Profile: Scopus | Orcid

Featured Publications

  • Kaya, G., Tunçel, A., Özel, D., Sert, B., Harputlu, E., Ünlü, C. G., Ocakoglu, K., & Yurt, F. (2025). Fucoidan-functionalized molybdenum carbide nanospheres for combined therapy: Photothermal, photodynamic, and chemotherapeutic effects on triple-negative breast cancer cell lines. International Journal of Biological Macromolecules.

  • Özel, D., & Yurt, F. (2025). Synthesis and characterization of manganese-loaded core-shell SPIONs for dual T1/T2 weighted MR imaging applications in breast cancer. Inorganic Chemistry Communications.

  • Özel, D., Tunçel, A., Kaya, G., Sert, B., Yilmaz, O., Aktas, S., Kolatan, H. E., Gokbayrak, Ö., Ünlü, C. G., & Yurt, F. (2025). Targeted therapy for glioblastoma: Synergistic effects of GO/C-TMZ,@, PmAb and magnetic hyperthermia. ACS Applied Bio Materials.

  • Tunçel, A., Sert, B., Özel, D., Kaya, G., Harputlu, E., Ünlü, C. G., Güleç, S., Yurt, F., & Ocakoglu, K. (2025). Enhanced glioblastoma treatment via carbon-coated perovskite nanohybrid: Synergistic effects of targeted chemotherapy and magnetic hyperthermia. Journal of Drug Delivery Science and Technology.

  • Özel, D., Sarıkahya, N. B., Tunçel, A., Nalbantsoy, A., & Yurt, F. (2025). Preparation and biodistribution of [131I]iodoelmalienoside a, a saponin-based adjuvant, in mice. Journal of Radioanalytical and Nuclear Chemistry.

  • Kaya, G., Tunçel, A., Özel, D., Sert, B., Harputlu, E., Ünlü, C. G., Ocakoglu, K., & Yurt, F. (2025). Assessment of Mo₂C@C@Fuc/Mo₂C-MXene@Fuc hybrid structures: Potential for photothermal and photodynamic applications. Surfaces and Interfaces.

  • Sezgin, E., Camgöz, B., & Yurt, F. (2025). Radiation dosimetry in 68Ga-PSMA PET/CT prostate imaging. Journal of Radioanalytical and Nuclear Chemistry.

  • Sert, B., Kaya, G., Çiçek, S., Harputlu, E., Şimşek, T., Tekgül, A., Ünlü, C. G., Yurt, F., & Ocakoglu, K. (2025). Influence of silane coating and graphene oxide integration on the magnetothermal behaviors of La1-xSrxMnO3 nanoparticles. Journal of Magnetism and Magnetic Materials.

Yi Yao | Nanomedicine | Best Researcher Award

Prof. Yi Yao | Nanomedicine | Best Researcher Award

Renmin Hospital of Wuhan University | China

Prof. Yi Yao is a distinguished oncologist, Ph.D., Chief Physician, and Director of the Cancer Center at Renmin Hospital of Wuhan University, China, with a career dedicated to advancing cancer treatment and research. He earned his medical degree and doctorate from Wuhan University and received international training as a Visiting Scholar at the German Cancer Research Center, Heidelberg University, and MD Anderson Cancer Center in the United States. His clinical and research interests focus on tumor radiotherapy and the tumor immune microenvironment, with particular emphasis on how irradiation influences tumor biology, radiotherapy efficacy, and radiation-induced lung injury, including the role of fibroblasts and tumor interstitial fibrosis in treatment outcomes. Prof. Yao has secured major research funding from the National Natural Science Foundation of China, the Hubei Natural Science Foundation, and multiple institutional projects, while building collaborations with world-leading cancer research centers in Germany and the United States. He has published extensively in high-impact journals such as Nature Communications, The EMBO Journal, Journal of Clinical Oncology, Cancer Medicine, Histopathology, Nano Letters, and Frontiers in Immunology, in addition to co-editing oncology volumes and holding software copyrights. Recognized with numerous national, provincial, and institutional awards for his contributions to research, clinical practice, and mentorship, Prof. Yao serves on national and provincial oncology committees, is a member of ASCO and ESMO, and continues to mentor doctoral and master’s students, making lasting contributions to oncology education, clinical innovation, and cancer research.

Profile: Orcid

Featured publications

  • Zhang, H., Chen, L., Li, L., Liu, Y., Das, B., Zhai, S., Tan, J., Jiang, Y., Turco, S., Yao, Y., & Frishman, D. (2025). Prediction and analysis of tumor infiltrating lymphocytes across 28 cancers by TILScout using deep learning. NPJ Precision Oncology, 9(1), 76.

  • Dong, Y., Khan, L., & Yao, Y. (2024). Immunological features of EGFR-mutant NSCLC and clinical practice. Journal of the National Cancer Center, 4(4), 289–298.

  • Yi, L., Wen, Y., Xiao, M., Yuan, J., Ke, X., Zhang, X., Khan, L., Song, Q., & Yao, Y. (2024). The proportion of tumour stroma predicts response to immune checkpoint inhibitor plus chemotherapy in stage IIIB–IV NSCLC. Histopathology, 85(2), 295–309.

  • Yao, Y., Shen, Y., Yao, J. C., & Zuo, X. (2024). Editorial: New advancement in tumor microenvironment remodeling and cancer therapy. Frontiers in Cell and Developmental Biology, 12, 1384567.

  • Li, Y., Chen, J., Wang, B., Xu, Z., Wu, C., Ma, J., Song, Q., Geng, Q., Yu, J., Pei, H., & Yao, Y. (2023). FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis. Drug Resistance Updates, 67, 100926.

  • Yao, Y., Chu, Y., & Xu, B. (2019). Radiotherapy after surgery has significant survival benefits for patients with triple-negative breast cancer. Cancer Medicine, 8(2), 554–563.

Assoc Prof Dr. Chong Qiu | Nanomedicine Awards | Young Scientist Award

Assoc Prof Dr. Chong Qiu | Nanomedicine Awards | Young Scientist Award

Assoc Prof Dr. Chong Qiu, China Academy of Chinese Medical Sciences, China

Associate Professor Chong Qiu, Ph.D., is a prominent researcher at the Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing. He earned his bachelor’s and doctoral degrees from the School of Pharmaceutical Science, Peking University, in 2014 and 2019, respectively. Dr. Qiu’s research focuses on advanced nanocarriers for targeted drug delivery, including siRNA and protein delivery systems. He is an active Young Scientist Board Member for several journals and has published extensively, with notable papers in Nature Communications and Journal of Nanobiotechnology. His work has garnered significant attention and impact in the fields of nanomedicine and drug delivery.

Professional Profile:

Orcid

Suitability Summary for Young Scientist Award: Associate Professor Chong Qiu

Associate Professor Chong Qiu is an exemplary candidate for the Young Scientist Award. His pioneering research in nanocarriers for drug delivery, combined with his impressive publication record and leadership roles, highlights his exceptional potential and influence in the scientific community. His achievements and innovative contributions make him a standout nominee for this prestigious award

🎓Education:

Dr. Chong Qiu earned his Ph.D. in Pharmaceutical Sciences from the School of Pharmaceutical Science at Peking University, Beijing, China, in 2019. He completed his Bachelor’s Degree in Pharmaceutical Sciences at the same institution in 2014.

🏢Work Experience:

Dr. Chong Qiu has been serving as an Associate Professor at the Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, since 2019. In addition to his role at the Research Center, he is an ongoing Young Scientist Board Member for the Asian Journal of Pharmaceutical Sciences, iMeta, and Traditional Medicine Research and Exploration

🏅Awards and Recognition:

Dr. Chong Qiu has an extensive publication record in high-impact journals, including notable works in Nature Communications and the Journal of Nanobiotechnology. His research has garnered significant recognition and has made substantial contributions to the fields of nanomedicine and drug delivery.

Publication Top Notes:

  • Photoaffinity Probe-Based Antimalarial Target Identification of Artemisinin in the Intraerythrocytic Developmental Cycle of Plasmodium falciparum
  • Enhanced Tumor Penetration Across the Blood-Brain Barrier: Endoplasmic Reticulum Membrane Hybrid siRNA Nanoplexes
  • Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery
  • Advanced Strategies for Nucleic Acids and Small-Molecular Drugs in Combined Anticancer Therapy
  • Anemoside B4 Alleviates Neuropathic Pain Through Inhibiting Inflammation